Atara Biotherapeutics, Inc. (LON:0HIY)
London · Delayed Price · Currency is GBP · Price in USD 11.92
-0.13 (-1.07%)
At close: Sep 12, 2025
Atara Biotherapeutics Company Description
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom.
Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases.
The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.
Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Atara Biotherapeutics, Inc.
| Country | United States |
| Founded | 2012 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 153 |
| CEO | Anhco Nguyen |
Contact Details
Address: 1280 Rancho Conejo Blvd Thousand Oaks, Delaware 91320 United States | |
| Phone | 805 623 4211 |
| Website | atarabio.com |
Stock Details
| Ticker Symbol | 0HIY |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US0465131078 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Anhco Nguyen | Chief Executive Officer |
| Yanina Grant-Huerta | Chief Financial Officer |
| Alex Chapman | Head of Investor Relations |